Reports Q1 revenue $257,884, consensus $2.63M. Coya‘s CEO commented, “We believe the new data from the IIT trial in patients with FTD and the promising COYA 303 data showing the synergistic potential of low dose IL-2 and GLP-1 RAs has added to the growing evidence that our approach to address Treg dysfunction using combination approaches holds high promise and increases our confidence in the clinical outcomes for COYA-302 in the larger ALS and FTD studies that are planned.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Promising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline Potential
- Coya Therapeutics reports interim results from IL-2, CTLA4-Ig combination study
- Coya Therapeutics announces publication of study results on COYA 303
- Atea Pharmaceuticals appoints Howard Berman to board of directors
- Coya Therapeutics provides update on exosome platform